ATE282045T1 - Verbindungen und verfahren zur hemmung von wechselwirkung zwischen alpha-catenin und beta- catenin - Google Patents

Verbindungen und verfahren zur hemmung von wechselwirkung zwischen alpha-catenin und beta- catenin

Info

Publication number
ATE282045T1
ATE282045T1 AT98914747T AT98914747T ATE282045T1 AT E282045 T1 ATE282045 T1 AT E282045T1 AT 98914747 T AT98914747 T AT 98914747T AT 98914747 T AT98914747 T AT 98914747T AT E282045 T1 ATE282045 T1 AT E282045T1
Authority
AT
Austria
Prior art keywords
catenin
beta
alpha
methods
compounds
Prior art date
Application number
AT98914747T
Other languages
English (en)
Inventor
Orest W Blaschuk
Barbara J Gour
Original Assignee
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcgill filed Critical Univ Mcgill
Application granted granted Critical
Publication of ATE282045T1 publication Critical patent/ATE282045T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT98914747T 1997-04-10 1998-04-14 Verbindungen und verfahren zur hemmung von wechselwirkung zwischen alpha-catenin und beta- catenin ATE282045T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4336197P 1997-04-10 1997-04-10
PCT/CA1998/000322 WO1998045319A2 (en) 1997-04-10 1998-04-14 COMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION BETWEEN α-CATENIN and β-CATENIN

Publications (1)

Publication Number Publication Date
ATE282045T1 true ATE282045T1 (de) 2004-11-15

Family

ID=21926779

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98914747T ATE282045T1 (de) 1997-04-10 1998-04-14 Verbindungen und verfahren zur hemmung von wechselwirkung zwischen alpha-catenin und beta- catenin

Country Status (8)

Country Link
US (2) US6551994B1 (de)
EP (1) EP0975660B1 (de)
AT (1) ATE282045T1 (de)
AU (1) AU6914798A (de)
CA (1) CA2286291A1 (de)
DE (1) DE69827485T2 (de)
ES (1) ES2232941T3 (de)
WO (1) WO1998045319A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610821B1 (en) 1996-07-12 2003-08-26 Mcgill University Compounds and methods for modulating endothelial cell adhesion
US6562786B1 (en) 1996-07-12 2003-05-13 Mcgill University Compounds and methods for modulating apoptosis
US6207639B1 (en) 1996-07-12 2001-03-27 Mcgill University Compounds and methods for modulating neurite outgrowth
US6465427B1 (en) 1996-07-12 2002-10-15 Mcgill University Compounds and methods for modulating cell adhesion
AU722985B2 (en) 1996-07-12 2000-08-17 Mcgill University Compounds and methods for modulating cell adhesion
US7122623B2 (en) 1996-07-12 2006-10-17 Adherex Technologies, Inc. Compounds and methods for modulating cell adhesion
US6346512B1 (en) 1996-07-12 2002-02-12 Mcgill University Compounds and methods for modulating cell adhesion
US6333307B1 (en) 1996-07-12 2001-12-25 Mcgill University Compounds and method for modulating neurite outgrowth
US20020168761A1 (en) 2000-01-24 2002-11-14 Gour Barbara J. Peptidomimetic modulators of cell adhesion
US6169071B1 (en) * 1996-07-12 2001-01-02 Mcgill University Compounds and methods for modulating cell adhesion
US6417325B1 (en) 1996-07-12 2002-07-09 Mcgill University Compounds and methods for cancer therapy
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6503881B2 (en) 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6551994B1 (en) 1997-04-10 2003-04-22 Mcgill University Compounds and methods for inhibiting the interaction between α-catenin and β-catenin
US6683048B1 (en) 1997-04-10 2004-01-27 Mcgill University Compounds and methods for stimulating gene expression and cellular differentiation
US6790829B1 (en) 1997-07-25 2004-09-14 Seatek Marine Biotechnology, Inc. Cyclic decapeptide antibiotics
US6203788B1 (en) 1997-09-29 2001-03-20 Adherex Inc. Compounds and methods for regulating cell adhesion
EP1054899A2 (de) 1998-02-21 2000-11-29 Max-Delbrück-Centrum Für Molekulare Medizin Mittel zur therapie von menschlichen erkrankungen, ausgehend von beta-catenin, seine herstellung und seine verwendung
EP1091762A1 (de) 1998-07-02 2001-04-18 Genzyme Corporation Expression von transgenen in polarisierten zellen
US6277824B1 (en) 1998-07-10 2001-08-21 Adherex Technologies Compounds and methods for modulating adhesion molecule function
JP2004513059A (ja) * 1998-12-24 2004-04-30 ユセベ，ソシエテ　アノニム ペプチド産物、方法及び組成物
WO2000059939A1 (en) * 1999-04-05 2000-10-12 Adherex Technologies Inc. COMPOUNDS AND METHODS FOR STIMULATING β-CATENIN MEDIATED GENE EXPRESSION AND DIFFERENTIATION
US6303576B1 (en) 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
CA2395143A1 (en) * 1999-12-23 2001-07-05 Frans Van Roy Novel cdnas encoding catenin-binding proteins with function in signalling and/or gene regulation
AU2001269106A1 (en) * 2000-07-12 2002-01-21 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Novel alpha expressed in heart and testis
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
ES2655833T3 (es) * 2004-05-11 2018-02-21 AbGenomics Coöperatief U.A. Epítopos que inducen la muerte de células T
EP2190868A4 (de) * 2007-07-31 2011-11-23 Cognosci Inc Verfahren zur hemmung von calcineurin mit apoe-analoga
WO2012082891A1 (en) 2010-12-14 2012-06-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic peptide inhibitors of wnt pathway
US20250222062A1 (en) * 2022-03-24 2025-07-10 The Translational Genomics Research Institute Peptide inhibitors targeting the tbl1-beta-catenin complex

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05500504A (ja) 1989-09-27 1993-02-04 アテナ・ニュウロサイエンスィズ・インコーポレイテッド 細胞付着阻止のための組成物及び使用方法
US5972884A (en) 1991-03-11 1999-10-26 Creative Biomolecules, Inc. Morphogen treatment of gastrointestinal ulcers
US5922855A (en) * 1993-12-17 1999-07-13 Oregon Health Sciences University Mammalian DNA mismatch repair genes MLH1 and PMS1
US5610281A (en) * 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
AU722985B2 (en) 1996-07-12 2000-08-17 Mcgill University Compounds and methods for modulating cell adhesion
CA2283932A1 (en) 1997-03-24 1998-10-01 Onyx Pharmaceuticals, Inc. Compositions and methods for diagnosing/treating disease based on beta-catenin/transcription factor interactions
US6551994B1 (en) * 1997-04-10 2003-04-22 Mcgill University Compounds and methods for inhibiting the interaction between α-catenin and β-catenin
US6683048B1 (en) * 1997-04-10 2004-01-27 Mcgill University Compounds and methods for stimulating gene expression and cellular differentiation
US6303576B1 (en) * 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression

Also Published As

Publication number Publication date
WO1998045319A3 (en) 1998-12-17
US7063842B2 (en) 2006-06-20
US20030236186A1 (en) 2003-12-25
CA2286291A1 (en) 1998-10-15
ES2232941T3 (es) 2005-06-01
EP0975660A2 (de) 2000-02-02
DE69827485T2 (de) 2005-10-27
EP0975660B1 (de) 2004-11-10
US6551994B1 (en) 2003-04-22
DE69827485D1 (de) 2004-12-16
AU6914798A (en) 1998-10-30
WO1998045319A2 (en) 1998-10-15

Similar Documents

Publication Publication Date Title
ATE282045T1 (de) Verbindungen und verfahren zur hemmung von wechselwirkung zwischen alpha-catenin und beta- catenin
WO2000002917A3 (en) Compounds and methods for modulating cadherin-mediated functions
WO1999057149A3 (en) Compounds and methods for modulating nonclassical cadherin-mediated functions
DK0724456T3 (da) CD40-Antistoffer
NO985459D0 (no) Antistoffer mot ED-B domenen til fibronektin samt konstruksjon og anvendelse derav
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
ATE473754T1 (de) Verfahren zur manipulation der zelldifferenzierung
ATE172743T1 (de) Nachweis von kollagenabbau -i(in vivo)
DE69431797D1 (de) Verfahren und Stoffe zur Modulation der immunsuppressiven Aktivität und Toxitätvon monoklonalen Antikörpern
DE69838689D1 (de) Verfahren zur Aktualisierung von Konten
DK0692025T3 (da) Gærceller, der er konstrueret således, at de producerer surrogater for proteiner i feromonsystemet, og anvendelser deraf
DE69624590D1 (de) Klebhilfsmittel und verfahren zur darstellung von klebhilfsmittel
ATE163679T1 (de) Anti-rezeptor antikörper gegen den vitamin b12/transcobalamin ii rezeptor
DE68913251D1 (de) Verfahren zur Verringerung der Heterogenität von monoklonalen Antikörpern.
DE69629688D1 (de) Chemoattraktion-auslösender faktor aus lymphozyten und dessen verwendungen
WO2001072956A3 (en) Compounds and methods for modulating desmosomal cadherin-mediated functions
DE69636631D1 (de) Verfahren zur Erzeugung und Registrierung von Grundschlüsseln
DE69942668D1 (de) Humanisierter monoklonaler antikörper gegen von-willebrand faktor
DE69808542D1 (de) Verfahren zur Ringöffnung von zyklischen Verbindungen
DK0802924T3 (da) Lægemiddel til forlænget immunsuppression og eliminering af tumorceller
ATE410514T1 (de) Calciumbindende rekombinante antikörper gegen protein c
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
ATE170631T1 (de) Verfahren und zusammensetzung zur verminderung der effekte von endogener alkalischer phosphatase
DE3860525D1 (de) Vorrichtung zur erschliessung von muelldeponiegasquellen und zur erkundung und sanierung von altlasten und verunreinigten boeden.
DE69433634D1 (de) Verfahren zur Umsetzung von Kohlenwasserstoffen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties